NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.8089
+0.0584 (7.78%)
At close: Apr 28, 2026, 4:00 PM EDT
0.7909
-0.0180 (-2.23%)
After-hours: Apr 28, 2026, 6:19 PM EDT
NeuroSense Therapeutics Market Cap
NeuroSense Therapeutics has a market cap or net worth of $28.59 million as of April 28, 2026. Its market cap has increased by 20.56% in one year.
Market Cap
28.59M
Enterprise Value
27.58M
1-Year Change
20.56%
Ranking
Category
Stock Price
$0.81
Market Cap Chart
Since the IPO on December 9, 2021, NeuroSense Therapeutics's market cap has decreased from $64.61M to $28.59M, a decrease of -55.74%. That is a compound annual growth rate of -16.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 27, 2026 | 26.53M | 16.16% |
| Dec 31, 2025 | 22.84M | -17.70% |
| Dec 31, 2024 | 27.75M | 158.68% |
| Dec 29, 2023 | 10.73M | -24.68% |
| Dec 30, 2022 | 14.24M | -46.24% |
| Dec 31, 2021 | 26.49M | -59.00% |
| Dec 9, 2021 | 64.61M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Apollomics | 28.32M |
| Lisata Therapeutics | 28.18M |
| Neuphoria Therapeutics | 27.76M |
| Lantern Pharma | 27.57M |
| NanoViricides | 26.99M |
| ABVC BioPharma | 26.69M |
| CEL-SCI | 26.38M |
| Longeveron | 26.35M |